ADA and psoriasis: Intervention: Randomized controlled trials (RCTs) evaluating the use of biological medications (Risankizumab, secukinumab, guselkumab, adalimumab, certolizumab, etanercept, ustekinumab, brodalumab, ixekizumab, tildrakizumab, infliximab, methotrexate, briakinumab, golimumab, bimekizumab and ADA) for the treatment of psoriasis.